恆天海龍(000677.SZ):裁定執行後 康南科技將成為公司第一大股東
格隆匯10月18日丨恆天海龍(000677.SZ)公佈,2019年10月18日,公司收到温州康南科技有限公司(“康南科技”)發來的(2019)遼01執1209號《遼寧省瀋陽市中級人民法院執行裁定書》,公司股票(證券代碼為000677)2億股的所有權歸買受人康南科技所有。
公司股票(證券代碼為000677)2億股的所有權自本裁定送達買受人康南科技時起轉移。買受人康南科技可持本裁定書到登記機構辦理相關產權過户登記手續。
此次裁定執行後,康南科技將持有公司2億股股份(佔公司總股本的23.15%),成為公司第一大股東。康南科技已聘請專業的中介機構準備《詳式權益變動報告書》等相關文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.